Literature DB >> 15258589

MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation.

Deborah N Chadee1, John M Kyriakis.   

Abstract

The ERK group of mitogen-activated protein kinases (MAPKs) is essential for cell proliferation stimulated by mitogens, oncogenic ras and raf (ref. 1). All MAPKs are activated by MAP3K/MEK/MAPK core pathways and the Raf proto-oncoproteins, especially B-Raf, are ERK-specific MAP3Ks (refs 1-3). Mixed lineage kinase-3 (MLK3) is a MAP3K that was thought to be a cytokine-activated, and comparatively selective, regulator of the JNK group of MAPKs (refs 1, 4-6). Here we report that silencing of mlk3 by RNAi suppressed mitogen and cytokine activation not only of JNK but of ERK and p38 as well. Silencing mlk3 also blocked mitogen-stimulated phosphorylation of B-Raf at Thr 598 and Ser 601, a step required for B-Raf activation. Furthermore, silencing mlk3 prevented serum-stimulated cell proliferation and the proliferation of tumour cells bearing either oncogenic Ki-Ras or loss-of-function neurofibromatosis-1 (NF1) or NF2 mutations. The proliferation of tumour cells containing activating B-raf or raf-1 mutations was unaffected by silencing mlk3. Our results define an unexpected role for MLK3 in mitogen regulation of B-Raf, ERK and cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15258589     DOI: 10.1038/ncb1152

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  71 in total

1.  A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody.

Authors:  T Hirohashi; C M Chase; P Della Pelle; D Sebastian; A Alessandrini; J C Madsen; P S Russell; R B Colvin
Journal:  Am J Transplant       Date:  2011-11-09       Impact factor: 8.086

Review 2.  PAK and other Rho-associated kinases--effectors with surprisingly diverse mechanisms of regulation.

Authors:  Zhou-shen Zhao; Ed Manser
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

3.  Metabolic stress signaling mediated by mixed-lineage kinases.

Authors:  Anja Jaeschke; Roger J Davis
Journal:  Mol Cell       Date:  2007-08-03       Impact factor: 17.970

Review 4.  The ERK cascade: a prototype of MAPK signaling.

Authors:  Hadara Rubinfeld; Rony Seger
Journal:  Mol Biotechnol       Date:  2005-10       Impact factor: 2.695

5.  Mixed Lineage Kinase 3 deficiency delays viral clearance in the lung and is associated with diminished influenza-induced cytopathic effect in infected cells.

Authors:  Emily A Desmet; Joseph A Hollenbaugh; Patricia J Sime; Terry W Wright; David J Topham; Andrea J Sant; Toru Takimoto; Stephen Dewhurst; Sanjay B Maggirwar
Journal:  Virology       Date:  2010-02-25       Impact factor: 3.616

6.  Molecular pathways: targeting the kinase effectors of RHO-family GTPases.

Authors:  Tatiana Y Prudnikova; Sonali J Rawat; Jonathan Chernoff
Journal:  Clin Cancer Res       Date:  2014-10-21       Impact factor: 12.531

7.  MLK3 limits activated Galphaq signaling to Rho by binding to p63RhoGEF.

Authors:  Katherine I Swenson-Fields; Joshua C Sandquist; Jessica Rossol-Allison; Irene C Blat; Krister Wennerberg; Keith Burridge; Anthony R Means
Journal:  Mol Cell       Date:  2008-10-10       Impact factor: 17.970

8.  IFN-γ-inducible antiviral responses require ULK1-mediated activation of MLK3 and ERK5.

Authors:  Diana Saleiro; Gavin T Blyth; Ewa M Kosciuczuk; Patrick A Ozark; Beata Majchrzak-Kita; Ahmet D Arslan; Mariafausta Fischietti; Neha K Reddy; Curt M Horvath; Roger J Davis; Eleanor N Fish; Leonidas C Platanias
Journal:  Sci Signal       Date:  2018-11-20       Impact factor: 8.192

9.  Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein.

Authors:  Deborah N Chadee; Dazhong Xu; Gene Hung; Ali Andalibi; David J Lim; Zhijun Luo; David H Gutmann; John M Kyriakis
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

10.  Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours.

Authors:  Sérgia Velho; Carla Oliveira; Joana Paredes; Sónia Sousa; Marina Leite; Paulo Matos; Fernanda Milanezi; Ana Sofia Ribeiro; Nuno Mendes; Danilo Licastro; Auli Karhu; Maria José Oliveira; Marjolijn Ligtenberg; Richard Hamelin; Fátima Carneiro; Annika Lindblom; Paivi Peltomaki; Sérgio Castedo; Simó Schwartz; Peter Jordan; Lauri A Aaltonen; Robert M W Hofstra; Gianpaolo Suriano; Elia Stupka; Arsenio M Fialho; Raquel Seruca
Journal:  Hum Mol Genet       Date:  2009-12-02       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.